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ABSTRACT
Here, we report new mechanistic insight into how chronic hypoxia increases 
‘stemness’ in cancer cells. Using chemical inhibitors, we provide direct experimental 
evidence that ROS production and mitochondrial biogenesis are both required for the 
hypoxia-induced propagation of CSCs. More specifically, we show that hypoxic CSCs 
can be effectively targeted with i) simple mitochondrial anti-oxidants (Mito-TEMPO) 
and/or ii) inhibitors of mitochondrial biogenesis (Doxycycline). In this context, 
we discuss the idea that mitochondrial biogenesis itself may be a primary driver 
of “stemness” in hypoxic cancer cells, with metabolic links to fatty acid oxidation 
(FAO). As Doxycycline is an FDA-approved drug, we propose that it could be re-
purposed to target hypoxic CSCs, either alone or in combination with chemotherapy, 
i.e., Paclitaxel. For example, we demonstrate that Doxycycline effectively targets the 
sub-population of hypoxia-induced CSCs that are Paclitaxel-resistant, overcoming 
hypoxia-induced drug-resistance. Finally, anti-angiogenic therapy often induces 
tumor hypoxia, allowing CSCs to survive and propagate, ultimately driving tumor 
progression. Therefore, we suggest that Doxycycline could be used in combination 
with anti-angiogenic agents, to actively prevent or minimize hypoxia-induced 
treatment failure. In direct support of this assertion, Paclitaxel is already known to 
behave as an angiogenesis inhibitor. 
INTRODUCTION
Hypoxia in the tumor microenvironment is a critical 
negative prognostic factor that ultimately promotes cancer 
progression, tumor recurrence and distant metastasis, as 
well as chemo- and radio-resistance [1, 2]. Therefore, 
many medicinal chemists, pharmacologists, biologists and 
clinicians have all sought to invent new “hypoxia-specific” 
therapeutics to target the hypoxic tumor microenvironment 
[3, 4]. However, these “hypoxia-specific” strategies and 
anti-cancer drugs still remain elusive. 
Perhaps another approach would be to better 
understand what are the basic cellular factors that 
make hypoxia such a strong driver of a lethal tumor 
microenvironment. For example, it is known that hypoxia 
can also induce stem cell characteristics in cancer cells [1-
4]. Thus, an increase in “stemness” may actually explain 
the clinical association of hypoxia with a poor prognosis 
and drug-resistance [1-7].
Here, we provide further mechanistic evidence to 
support the role of hypoxia in driving CSC propagation. In 
addition, we show that chronic hypoxia in CSCs induces 
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a specific stress response, which leads to i) increased ROS 
production and ii) elevated mitochondrial biogenesis. 
Remarkably, treatment of these hypoxic CSCs with ROS 
scavengers (Mito-TEMPO) [8] or an FDA-approved 
inhibitor of mitochondrial biogenesis (Doxycycline) [9-
11] effectively blocks the propagation of hypoxic CSCs. 
We discuss the possibility that Doxycycline could 
be re-purposed as an anti-cancer agent to specifically 
target hypoxic CSCs, either alone or in combination 
with other chemo-therapeutic agents, such as Paclitaxel. 
Moreover, we directly demonstrate that Doxycycline 
effectively targets the sub-fraction of hypoxic CSCs that 
are Paclitaxel-resistant. 
RESULTS
Chronic hypoxia stimulates mitochondrial 
biogenesis and CSC propagation
In this report, we systematically examine the role of 
chronic hypoxia and oxidative stress in the propagation of 
breast CSCs, using a human tumor cell-line (MCF7 cells) 
— as a model system (summarized in Figure 1). 
As a first step, MCF7 cell monolayers were 
subjected to hypoxia (1% oxygen) for increasing periods 
of time (0, 6, 24, 48, 72 and 96 hours). MCF7 cell 
monolayers were then trypsinized and subjected to FACS 
analysis with MitoTracker Deep-Red-FM as a probe, to 
estimate their mitochondrial mass. 
Figure 2 shows that 6, 24 and 48 hours of hypoxia 
have little or no effect on mitochondrial mass. In contrast, 
chronic hypoxia increased mitochondrial mass by up 
to ~2-fold, at 72 and 96 hours of oxygen-deprivation. 
A representative FACS tracing is shown in Figure 2F, 
demonstrating a clear shift to the right. This was confirmed 
by immuno-blot analysis with TOMM20, an established 
marker of mitochondrial mass. Therefore, it appears that 
chronic hypoxia, for 3 to 4 days, preferentially stimulates 
mitochondrial biogenesis. 
We next performed a time course of hypoxia versus 
CSC activity, using the mammosphere assay as a read-
out. Initially, MCF7 cell monolayers were cultured under 
conditions of acute and chronic hypoxia. Then, the cells 
were trypsinized and re-seeded into low-attachment plates, 
to detect and quantitatively measure 3D mammosphere 
forming activity. 
Remarkably, Figure 3A shows that acute hypoxia 
(6 hours) actually inhibits mammosphere formation 
by >60%. In contrast, Figure 3B, 3C demonstrates that 
chronic hypoxia (72 and 96 hours) clearly stimulates 
mammosphere formation, by >1.5-fold. As such, chronic 
hypoxia appears to drive mitochondrial biogenesis and an 
increase in cancer stem cell activity, suggesting that these 
two processes may be functionally linked. 
Doxycycline, an inhibitor of mitochondrial 
biogenesis, targets and halts the propagation of 
hypoxia-induced CSC activity
To test the hypothesis that mitochondrial biogenesis 
is required for hypoxia-induced CSC propagation, we 
next used the FDA-approved antibiotic Doxycycline. 
Doxycycline inhibits protein synthesis in bacteria by 
targeting their ribosomes [6, 7, 9]. However, because of 
the conserved structural similarities between bacterial 
and mitochondrial ribosomes, Doxycycline also inhibits 
mitochondrial biogenesis, as an off-target side-effect in 
mammalian cells [6, 7, 9].
Importantly, Figure 4 shows that Doxycycline 
treatment effectively inhibits hypoxia-induced 
mammosphere formation, even more effectively than 
under normoxic conditions. Therefore, Doxycycline is 
effective after both normoxic and hypoxic pre-treatment 
conditions, but is actually more effective after chronic 
hypoxia treatment. Therefore, Doxycycline could be 
re-purposed to target the propagation of hypoxic CSCs, 
which are normally strongly resistant to conventional 
chemotherapy. 
Figure 1: Experimental approach. To understand the 
mechanism(s) underpinning the effects of hypoxic stress on 
CSC propagation, we used an unbiased metabolic phenotyping 
approach. Briefly, MCF7 cells were first subjected to acute 
hypoxia (for 6, 24 and 48 hrs) or chronic hypoxia (for 72 and 
96 hrs) grown as monolayers. Then, the hypoxic cells were 
harvested and subjected to anchorage-independent growth assays 
(mammosphere formation), to measure cancer stem cell activity. 
A variety of other metabolic parameters were also quantitated to 
pinpoint possible targets for therapeutic interventions. 
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Figure 2: Chronic hypoxia increases mitochondrial mass. MCF7 cells were cultured in Normoxia (21% O2) or Hypoxia (1% O2) 
for 6 h A., 24 h B., 48 h C., 72 h D. and 96 h E. and then mitochondrial mass was quantitated by FACS analysis using the probe MitoTracker 
Deep-Red (640-nm). F. Representative tracing showing a clear shift to the right for mitochondrial mass in MCF7 cells cultured for 96 h in 
low oxygen as compared to MCF7 cultured for 96 h in normoxic conditions. Data shown are the mean ± SEM of 3 independent experiments 
performed in triplicate. (***) p<0.001.  Evaluation of the mitochondrial protein TOMM20 in MCF7 cells cultured in Normoxia (21 % O2) 
or Hypoxia (1 % O2) for 6 G. and 96 h H. Side panels show densitometric analysis of the blots normalized to β-actin. Data shown are the 
mean ± SEM of 3 independent experiments. (**) p < 0.01.
Figure 3: Mammosphere formation is reduced after acute hypoxia and increased after prolonged hypoxia. Evaluation of 
mammosphere formation in MCF7 cells which were cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 6 h A., 72 h B. or 96 h C. and 
then seeded in low attachment plate for 5 days before counting. Data shown are the mean ± SEM of 3 independent experiments performed 
in triplicate. (***) p < 0.001.
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Note that 3 mitochondrial ribosomal proteins (MRPL4, MRPS35 and MRPL47) were all up-regulated in response to chronic hypoxia. 
Other proteins related to mitochondrial biogenesis were up-regulated, including: HYOU1, YARS2, NDUFV2, LONP1, POLRMT, 
COQ9, SARS2, HSPA9, HSPD1, ATP5J, and ATPAF1. A specific inhibitor of mitophagy, namely LRPPRC, which prevents the au-
tophagic digestion of mitochondria, was also up-regulated.
Figure 4: Doxycycline inhibits the formation of mammosphere induced by prolonged hypoxia. Evaluation of mammosphere 
formation in MCF7 cells which were cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 72 h A. or 96 h B. and then seeded in low 
attachment plate in the presence of Vehicle (-) or Doxycycline (Doxy, 50 µM) for 5 days before counting. Data shown are the mean ± SEM 
of 3 independent experiments performed in triplicate. (***) p < 0.001.
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Doxycycline increases the sensitivity of hypoxic 
CSCs to conventional chemotherapies, such as 
paclitaxel
We next investigated the implications of our findings 
for clinical treatments with chemotherapy. Hypoxic 
CSCs are known to be highly resistant to conventional 
chemotherapies, such as Paclitaxel [1-4, 12]. We were also 
able to demonstrate this drug-resistance, in the context of 
hypoxia. 
Figure 5 directly demonstrates that a significant 
fraction of CSCs are clearly resistant to treatment with 
Pactlitaxel and that this chemo-resistance is exacerbated, 
especially after MCF7 cells are exposed to chronic 
hypoxia. If we use 0.1 μM Paclitaxel, approximately 
50% of the hypoxic CSCs remain Paclitaxel-resistant 
(Figure 5B). Remarkably, addition of as little as 2 μM 
Doxycycline removes 50% of the Paclitaxel-resistant CSC 
activity; similarly, addition of 10 μM Doxycycline inhibits 
>75% of the Paclitaxel-resistant CSC activity (Figure 5C). 
Therefore, we propose that Doxycycline could 
be used as an add-on to Paclitaxel-treatment, to combat 
Paclitaxel drug-resistance, normally induced by the 
hypoxic tumor microenvironment. 
Metabolic phenotyping and proteomic profiling of 
cancer cells exposed to chronic hypoxia
To better assess the metabolic state after chronic 
hypoxia treatment (96 hours), we next subjected MCF7 
cell monolayers to metabolic flux analysis, using the 
Seahorse XFe96. Interestingly, oxygen-consumption rates 
Figure 5: Doxycycline increases hypoxic CSCs sensitivity to paclitaxel treatment. A. Evaluation of mammosphere formation 
in MCF7 cells which were cultured in Normoxia (21% O2) or Hypoxia (1% O2) 96 h (A) and then seeded in low attachment plate in the 
presence of Vehicle (-) or Paclitaxel (0.5 µM) for 5 days before counting. Note that CSCs obtained upon hypoxic conditions are more 
resistant to Paclitaxel. (***) p < 0.001. B. Evaluation of mammosphere formation in MCF7 cells which were cultured in Hypoxia (1% 
O2) 96 h (B) and then seeded in low attachment plate in the presence of Vehicle (-) or increasing concentrations of Paclitaxel (0.1 to 
0.5 µM) for 5 days before counting. Data shown are the mean ± SEM of 3 independent experiments performed in triplicate. (***) p < 
0.001. C. Evaluation of mammosphere formation in MCF7 cells which were cultured in Hypoxia (1% O2) for 96 h (C) and then seeded 
in low attachment plate in the presence of Vehicle (-) or Paclitaxel (0.1 µM), alone and in combination with increasing concentration of 
Doxycycline (2 µM to 10 µM) for 5 days before counting. Note that Doxycycline increases the sensitivity of hypoxic CSCs to paclitaxel 
treatment. Data shown are the mean ± SEM of 3 independent experiments performed in triplicate. (***) p < 0.001. 
Oncotarget6www.impactjournals.com/oncotarget
(OCR) in normoxia were severely impaired after 96 hours 
of hypoxic treatment, resulting in a ~60% reduction in 
ATP production (Figure 6). Similarly, glycolysis rates, as 
measured by ECAR (extracellular acidification rate), were 
also dramatically reduced by >60% (Figure 7). Therefore, 
MCF7 cells after chronic hypoxia appeared to be in a more 
quiescent metabolic state. 
Consistent with these functional metabolic 
observations, unbiased proteomics analysis revealed 
the up-regulation of 45 mitochondrial-related metabolic 
proteins. This is most likely related to a hypoxia-
induced stress response, driving increased mitochondrial 
biogenesis. 
More specifically, Table 1 shows that 3 
mitochondrial ribosomal proteins (MRPL4, MRPS35 and 
MRPL47) were all up-regulated in response to chronic 
hypoxia. Eleven other proteins related to mitochondrial 
biogenesis were up-regulated, including: HYOU1, 
YARS2, NDUFV2, LONP1, POLRMT, COQ9, SARS2, 
HSPA9, HSPD1, ATP5J, and ATPAF1. Also, a specific 
inhibitor of mitophagy, namely LRPPRC, which prevents 
the autophagic digestion of mitochondria, was up-
regulated. 
Interestingly, HYOU1 (Hypoxia up-regulated 
protein 1) was over-expressed by >170-fold. Importantly, 
HYOU1 (a.k.a., Orp150) is a mitochondrial chaperone 
protein that belongs to the heat shock protein 70 family, 
which is known to be involved in mitochondrial protein 
folding and confers cyto-protection under hypoxic 
conditions [13, 14]. In addition, other proteins that are part 
of the OXPHOS complexes were also up-regulated, such 
as NDUFV2, which was increased by nearly 7-fold. 
Figure 7: Glycolysis is reduced in MCF7 cells exposed to chronic hypoxia. The metabolic profile of MCF7 cells cultured in 
Normoxia (21% O2) or Hypoxia (1% O2) for 96 h, as assessed using the Seahorse XF-e96 analyzer. Representative tracing of metabolic flux 
A. Significant decrease in glycolysis and glycolytic reserve was observed B. Data shown are the mean ± SEM of 3 independent experiments 
performed in sextuplicate. (**) p < 0.01.
Figure 6: Mitochondrial respiration is inhibited in MCF7 cells exposed to chronic hypoxia. The metabolic profile of MCF7 
cells cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 96 h, as assessed using the Seahorse XF-e96 analyzer. Representative tracing 
of metabolic flux. A. Significant reduction in basal respiration, proton leak, maximal respiration and ATP levels was observed in MCF7 
cells cultured upon Hypoxia vs MCF7 cells cultured upon Normoxia. B. Data shown are the mean ± SEM of 3 independent experiments 
performed in sextuplicate. (*) p < 0.05; (**) p < 0.01.
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Chronic hypoxia induces CSC markers, such as 
ALDH
ALDH activity is now a well-established CSC 
marker for detecting and enriching CSC activity by flow-
cytometry [15-17]. ALDH activity can be measured by 
FACS, analysis using the Aldefluor fluorescent probe [15-
17]. Consistent with our current observations that chronic 
hypoxia increases mammosphere formation by >1.5-fold, 
we also observed a >1.5-fold increase in the number of 
ALDH(+) cells by FACS (Figure 8). 
Chronic hypoxia induces oxidative stress: Mito-
TEMPO, a mitochondrial anti-oxidant, halts 
mammosphere formation
To better understand the mechanism(s) underpinning 
how chronic hypoxia drives an increase in cancer stem 
cell activity, we hypothesized that oxidative stress might 
be the ‘root cause’. To test this hypothesis directly, we 
quantitatively measured ROS production after acute 
hypoxia (6 hours) and after chronic hypoxia (96 hours), 
using the probe CM-H2DCFDA by FACS analysis. 
Figure 8: Chronic hypoxia increases the CSC marker ALDH. Evaluation of ALDEFLUOR activity, an independent 
marker of CSCs in MCF7 cells cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 72 h A.. Each sample was normalized using 
diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as negative control. The tracing of representative samples is shown B. Data 
shown are the mean ± SEM of 3 independent experiments performed in triplicate. (*) p < 0.05.
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Interestingly, Figure 9A-9D shows that chronic hypoxia 
induces a >1.5-fold increase in ROS production, but that 
there is no increase in ROS production after acute hypoxia. 
To determine if oxidative stress drives the observed 
hypoxia-induced increase in ‘stemness’, we also examined 
if simple anti-oxidants can inhibit mammosphere 
formation. For this purpose, we used TEMPO-derivatives 
that behave as membrane-permeable SOD-mimetic 
agents, which scavenge superoxide anions and other free 
radicals. Figure 9E demonstrates that both i) 4-hydroxy-
TEMPO and ii) Mito-TEMPO effectively inhibited 
mammosphere formation by >70%, at a concentration of 
100 μM. Importantly, Mito-TEMPO is a mitochondrially-
targeted form of TEMPO, which contains a chemical 
mitochondrial targeting signal [8]. Therefore, we conclude 
that mitochondrial oxidative stress appears to be one of 
the key underlying causes of hypoxia-induced ‘stemness’. 
Figure 9: Higher ROS levels ‘boost’ hypoxic CSC propagation. Evaluation of ROS levels by FACS analysis using the CM-
H2DCFDA probe in MCF7 cells cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 6 h A. and 96 h C. Note that prolonged hypoxia 
significantly increases ROS levels. B., D. Representative tracing showing a clear shift to the right for mitochondrial mass in MCF7 cells 
cultured for 96 h in low oxygen as compared to MCF7 cultured for 96 h in normoxic conditions. Mammosphere formation is inhibited in 
MCF7 cells cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 96 h E. in the presence of Vehicle (-) and the mitochondria-targeted 
superoxide scavenger Mito-TEMPO (100 µM) or 4-Hydroxy-TEMPO (100 µM) (C). Data shown are the mean ± SEM of 3 independent 
experiments performed in triplicate. (***) p < 0.001.
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Chronic hypoxia activates p44/42-MAPK 
signalling, without modifying HIF-1α expression
HIF1-alpha is a well-known transcriptional mediator 
of the acute effects of hypoxia, but its functional role in 
chronic hypoxia is less well defined [18-22]. Therefore, 
we monitored the expression levels of HIF1-alpha in 
this context, by immunoblot analysis. We also measured 
p-ERK-1/2 activation, using phospho-specific antibody 
probes, for comparison purposes. 
Interestingly, Figure 10 shows that HIF1-alpha is 
strongly upregulated during acute hypoxia, as expected, 
but it remains undetectable during chronic hypoxia. 
Conversely, the levels of activated phospho-ERK-1/2 
were unchanged by acute hypoxia, but were significantly 
elevated by chronic hypoxia. Thus, these two very 
different signalling molecules may contribute to metabolic 
signalling at different phases of the hypoxia-induced stress 
response. The activation of ERK-1/2 by chronic hypoxia 
may provide a key stimulus for enhancing anchorage-
independent growth. 
Investigating the role of fatty acid oxidation 
(FAO) in mitochondrial biogenesis and CSC 
propagation
Fatty acid oxidation (FAO) is the process by 
which fatty acids are catabolized in mitochondria and 
peroxisomes, to generate Acetyl-CoA, which can then 
enter the TCA/Krebs cycle. In this process, the energy 
generated for each Acetyl-CoA molecule oxidized, results 
in 1 GTP and 11 ATP molecules.
Further bioinformatics analysis of the high-
resolution proteomics data presented in Table 1 reveals 
that a significant number of metabolic enzymes related 
to mitochondrial FAO are up-regulated during chronic 
hypoxia. More specifically, twelve mitochondrial proteins 
involved in FAO were induced by chronic hypoxia, 
Figure 10: Prolonged hypoxia activates MAPK signalling, without modifying HIF-1α expression. Evaluation of ERK1/2 
phosphorylation in MCF7 cells cultured in Normoxia (21% O2) or Hypoxia (1% O2) for 6h A. and 96 h B. Side panels show densitometric 
analysis of the blots normalized to ERK2. Evaluation of HIF-1α expression in MCF7 cells cultured in Normoxia (21% O2) or Hypoxia (1% 
O2) for 6 h C. and 96 h D. Side panels show densitometric analysis of the blots normalized to β-actin. Data shown are the mean ± SEM of 
3 independent experiments. (*) p < 0.05; (**) p < 0.01.
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including: HIBADH, ACADSB, ACAD9, ACADVL, 
HADH, PCCB, DECR1, ACOT9, ACADM, ACSM2B, 
SUCLG2 and CPT2. This is summarized in more detail 
in Table 2. 
These results suggest that FAO may be intimately 
related to mitochondrial biogenesis and CSC propagation. 
To test this hypothesis independently of hypoxia, we 
next used another distinct, more direct, stimulus to drive 
increased FAO and mitochondrial biogenesis. For this 
purpose, MCF7 cells were treated with Valproic acid, an 
FDA-approved drug commonly used for the treatment of 
epilepsy. In this context, Valproic acid is thought to behave 
as a fatty acid, stimulating FAO. In fact, Valproic acid is 
chemically-classified as a branched short-chain fatty acid. 
Figure 11A shows that treatment with increasing 
concentrations of Valproic acid (0, 1, 2.5 and 5 mM) is 
indeed sufficient to stimulate mitochondrial biogenesis, 
resulting in an up to 3-fold increase in mitochondrial 
mass. Similarly, addition of Valproic acid increased 
mammosphere formation, by up to 2-fold (Figure 11B). 
As the effects we observed were near maximal at 2.5 mM 
and some toxicity was observed at 5 mM, we decided to 
perform all subsequent experiments with 2.5 mM Valproic 
acid. At 2.5 mM, Valproic acid increased ALDH activity 
by >1.5-fold, consistent with an increase in ‘stemness’ 
(Figure 11C, 11D). 
To validate the idea that Valproic acid increased 
CSC propagation by a metabolic mechanism, we used 
two distinct inhibitors of FAO, namely Etomoxir and 
Perhexiline, both of which specifically target the enzyme 
Figure 11: Valproic acid increases mitochondrial mass and induces ‘stemness’ features. A. Mitochondrial mass. MCF7 cells 
were treated for 72 h with Vehicle or increasing concentrations of Valproic Acid (1 to 5 mM). Then, mitochondrial mass was evaluated by 
FACS analysis using the probe MitoTracker Deep-Red (640-nm). Inset displays a representative tracing showing a clear shift to the right 
for mitochondrial mass in MCF7 cells treated with 2.5 mM Valproic Acid vs MCF7 treated with Vehicle. B. Mammosphere formation. 
MCF7 cells which were treated with Vehicle or increasing concentrations of Valproic Acid (1 to 5 mM) for 72 h. Then, treatments were 
removed and cells were incubated in regular medium for additional 72 h before seeding in low attachment plate for 5 days in the presence 
of treatments. C. ALDEFLUOR activity, an independent marker of CSCs. MCF7 cells were treated with vehicle and Valproic Acid (2.5 
mM) for 72 h. Each sample was normalized using diethylaminobenzaldehyde (DEAB), a specific ALDH inhibitor, as negative control. The 
tracing of representative samples is shown D. In panels A-C, data shown are the mean ± SEM of 3 independent experiments performed in 
triplicate. (***) p < 0.001.
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CPT (carnitine O-palmitoyltransferase). Interestingly, 
Perhexiline is used clinically in New Zealand and 
Australia, as a preventative treatment for ischemic heart 
disease. 
Figure 12A, 12B shows that Etomoxir (200 μM) 
and Perhexiline (0.1, 1 and 10 μM) effectively inhibit 
both basal and Valproic acid augmented CSC propagation. 
Similar results were also obtained with Doxycycline (50 
μM), which functions to inhibit mitochondrial biogenesis 
(Figure 12A). 
Glycolysis is normally required to provide 
additional TCA cycle intermediates for the mitochondrial 
processing of Acetyl-CoA. Consistent with this idea, 
treatment with glycolysis inhibitors (2-DG or Vitamin C 
(ascorbic acid)) was also sufficient to inhibit Valproic acid 
augmented CSC propagation (Figure 12C). Under these 
conditions the IC-50 for 2-DG was 10 mM, while the 
IC-50 for Vitamin C was ~0.5 mM. If we compare with 
our previously published results under basal conditions 
[10], Vitamin C was 2X as potent under Valproic acid 
augmented conditions. 
In summary, it appears that both mitochondrial 
biogenesis and CSC propagation are metabolically linked 
to FAO, which can be functionally stimulated by Valproic 
acid (an FDA-approved drug) and inhibited by CPT 
inhibitors, such as Etomoxir and Perhexiline. Interestingly, 
the use of doxycycline or glycolysis inhibitors (2-DG and 
Vitamin C) was also sufficient to override the stimulatory 
effects of Valproic acid on CSC propagation. 
DISCUSSION
Repositioning the FDA-approved antibiotic 
Doxycycline to target hypoxic CSCs
Here, we report a new mechanism underlying how 
prolonged hypoxia drives the onset of enhanced stem cell 
characteristics in cancer cells. This prolonged or chronic 
hypoxia leads to elevated ROS production and oxidative 
stress, which in turn drives increased mitochondrial 
biogenesis as a stress response. More specifically, this 
hypoxic stress response fosters an increase in overall 
Figure 12: Inhibitors of fatty acid oxidation (FAO), mitochondrial biogenesis and glycolysis all block Valproic acid 
driven CSC propagation. A., B. Evaluation of mammosphere formation in MCF7 cells which were treated with Vehicle or Valproic 
Acid (2.5 mM) for 72 h. Then, the cells were allowed to recover in regular medium for additional 72 h and subsequently seeded in low 
attachment plate for 5 days in the presence of Valproic Acid, alone and in combination with the mitochondrial inhibitor (A) Doxycycline 
(50 µM), or the carnitine palmitoyltransferase-1 inhibitors (A) Etomoxir (200 µM), and (B) Perhexiline (0.1 to 10 µM). C. Evaluation of 
mammosphere formation in MCF7 cells which were treated with Vehicle or Valproic Acid (2.5 mM) for 72 h. Then, the cells were allowed 
to recover in regular medium for additional 72 h and subsequently seeded in low attachment plate for 5 days in the presence of Valproic 
Acid, alone and in combination with the glycolysis inhibitors 2-Deoxy-glucose (2-DG, 10 mM) and Ascorbic Acid (0.5 to 1 mM). Data 
shown are the mean ± SEM of 3 independent experiments performed in triplicate. (***) p < 0.001.
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mitochondrial mass in CSCs. Based on these new 
mechanistic observations, we next employed two well-
established small molecules to directly target oxidative 
stress and mitochondrial protein synthesis, in hypoxic 
CSCs. As a consequence, we now demonstrate that i) 
Mito-TEMPO (a mitochondrial anti-oxidant) [8] and ii) 
Doxycycline (an antibiotic that inhibits mitochondrial 
protein translation) [9-11] can both be used to functionally 
target hypoxic CSCs (summarized in Figure 13). 
Therefore, we propose that Doxycycline is a non-
toxic FDA-approved antibiotic that could be re-positioned 
to specifically eradicate hypoxic CSCs. We envision that 
Doxycycline would be used alone or in combination with 
other chemotherapy agents, such as Paclitaxel. In fact, 
we show here that Doxycycline can be used to target the 
Paclitaxel-resistant sub-population of hypoxic CSCs. 
Implications of Doxycycline for combating anti-
angiogenic therapy resistance
Over the last decade, anti-angiogenic therapies have 
emerged as promising anti-cancer agents, based on their 
ability to target tumor blood vessels, depriving cancer 
cells of essential nutrients [23-26]. However, clinical and 
pre-clinical data now questions the long-term benefits of 
anti-angiogenic therapies. For example, administration 
of anti-angiogenic agents has been shown to actually 
increase tumor invasiveness and metastasis [23-26]. The 
mechanistic explanation for the failure of angiogenesis 
inhibitors is their ability to generate intra-tumoral hypoxia, 
which then stimulates CSC survival and propagation [23-
26]. 
Indeed, environmental stressors like chronic hypoxia 
activate a complex response, that includes the stimulation 
of an “emergency” biochemical and biological programs. 
Under these conditions, cancer cells survive by entering 
into a transient quiescent state, which is reversed when 
appropriate environmental conditions are sufficient to 
support cell proliferation and ultimately metastasis [27]. 
As such, the effectiveness of anti-angiogenic agents could 
be improved by using combination strategies aimed at 
inhibiting both cancer- and cancer stem-like cells. Based 
on our current observations, we suggest the combined 
use of Doxycycline, with angiogenesis inhibitors, such as 
Bevacizumab (Avastin). This new proposed combination 
therapy would effectively block both: i) blood vessel 
formation and ii) CSC propagation, ultimately making 
anti-angiogenic therapy more effective. 
Additionally, our data indicate that Doxycycline’s 
inhibitory action on CSC propagation is particularly 
efficient after a hypoxic stress as compared with normoxic 
conditions, suggesting that anti-angiogenic agents, by 
generating intratumoral hypoxia, could sensitize the 
dormant CSCs to the inhibitory effects of mitochondria 
targeting agents. Although further validation of this 
therapeutic strategy is needed, the use of mitochondrial 
biogenesis inhibitors could ultimately allow anti-
angiogenic drugs to fulfill their therapeutic potential. 
In order to eradicate hypoxic cancer cells, many 
other investigators have sought to generate novel 
therapeutics that specifically interfere with HIF1-alpha 
function, the major hypoxia-induced transcription factor 
Figure 13: Schematic diagram summarizing the role 
of ROS production, oxidative stress and mitochondrial 
biogenesis in maintaining “stemness” in cancer cells. 
Here, we show that the propagation of hypoxic CSCs can be 
effectively targeted and halted with i) a mitochondrial anti-
oxidant (Mito-TEMPO) or ii) an inhibitor of mitochondrial 
biogenesis (Doxycycline). 
Figure 14: Schematic diagram summarizing the 
role of fatty acid oxidation (FAO) in driving CSC 
propagation. Here, we show that mitochondrial biogenesis 
and the propagation of CSCs can be stimulated by Valproic acid 
(VA, an FDA-approved drug), which is a branched short-chain 
fatty acid. Moreover, we demonstrate that VA-induced CSC 
propagation can be blocked by inhibitors of i) FAO (Etomoxir 
and Perhexiline), ii) mitochondrial biogenesis (Doxycycline) 
and/or iii) glycolysis (2-DG and Vitamin C). Importantly, 
Perhexiline and Doxycycline are used clinically for other 
medical indications, so they could be re-purposed. Vitamin C is 
a micronutrient that is also readily available (over-the-counter) 
and can be used safely, at relatively high oral or i.v. dosages. 
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[18, 19]. However, based on our current findings, HIF1-
apha is preferentially expressed only during the acute 
phase of hypoxia (6 hours), but is virtually undetectable 
or completely absent, under conditions of chronic hypoxia 
(96 hours). Instead, we find that phospho-ERK-1/2 is 
hyper-activated during chronic hypoxia, but not during 
acute hypoxia, showing just the opposite activation pattern 
as HIF1-apha. Based on these findings, we conclude that 
HIF1-apha inhibitors may not be that clinically relevant 
for the targeting of hypoxic CSCs, especially under 
chronic conditions, since the actions of HIF1-alpha appear 
to be largely confined to acute hypoxia. 
Linking mitochondrial biogenesis to CSC 
propagation and asymmetric cell division
During our hypoxia experiments, we observed 
that MCF7 cells subjected to chronic hypoxia (for 96 
hours) have dramatically reduced metabolic activity, 
characterized by very low levels of both i) mitochondrial 
oxygen consumption and ii) glycolysis; this finding is 
suggestive of a more quiescent metabolic state. In contrast, 
chronically hypoxic MCF7 cells showed marked increases 
in mitochondrial mass, a surrogate marker of mitochondrial 
biogenesis. Therefore, increased mitochondrial biogenesis 
may be a primary driver of increased “stemness”, rather 
than augmented cell metabolism. 
In direct support of this ‘working hypothesis’, 
Sabatini, Weinberg and colleagues have shown that 
new mitochondrial biogenesis is absolutely required for 
asymmetric cell division in CSCs [28]. More specifically, 
they observed that during asymmetric cell division, new 
CSCs retain the newly-generated mitochondria, while 
the old mitochondria are transferred during cytokinesis 
to the non-stem cells (or daughter cells) [28]. Therefore, 
inhibition of mitochondrial biogenesis should block 
asymmetric cell division, reducing “stemness”. This 
mechanistic interpretation would directly explain why 
Doxycycline is so effective at halting mammosphere 
formation, which is strictly dependent on asymmetric cell 
division in CSCs. 
Dissecting the functional role of FAO in 
mitochondrial biogenesis and CSC propagation
Since we observed that hypoxia specifically 
induced >10 mitochondrial enzymes associated with FAO 
(Table 2), we used Valproic acid as an independent and 
experimentally convenient means to activate FAO. 
Valproic acid (2-propylpentanoic acid) is a simple 
fatty acid, which functions as a substrate for fatty acid 
beta-oxidation (FAO) [29-32]. Valproic acid is completely 
metabolized by mitochondria, indicating that it can 
directly function as a mitochondrial fuel for FAO [28-32]. 
This FDA-approved drug is widely-used clinically for the 
management of patients with epilepsy. 
Although Valproic acid has been shown to elicit 
anti-proliferative and anti-apoptotic actions in diverse 
cancer cell systems [33-34], its actual effectiveness as an 
anti-cancer agent is still a controversial and hotly-debated 
topic, as suggested by several recent clinical trials [35-
37]. On the other hand, Valproic acid has been shown to 
increase the CSC population in glioblastoma cells and to 
“reprogram” differentiated triple-negative breast cancer 
cells to become quiescent stem-like cancer cells [38-39]. 
Supporting these studies, an increase in cell migration, 
invasion and a switch towards the epithelial-mesenchymal 
transition (EMT) phenotype has been detected, in various 
cancer cells treated with Valproic acid [40-41].
Interestingly, we observed here that treatment of 
MCF7 cells with Valproic acid was indeed sufficient to 
increase both i) mitochondrial biogenesis and ii) CSC 
propagation. The Valproic acid induced increase in CSC 
propagation that we observed could be halted by using 
well-established inhibitors of FAO, namely Etomoxir and 
Perhexiline, that target the enzyme CPT (summarized in 
Figure 14). Importantly, Etomoxir and Perhexiline also 
inhibited basal CSC propagation, that was not induced by 
Valproic acid. 
Therefore, based on the above experimental 
evidence, we believe that FAO is also a critical source 
of metabolic energy for fueling the propagation of 
CSCs. Perhexiline is used clinically, in New Zealand and 
Australia, as a prophylactic anti-anginal agent. As such, 
Perhexiline could be re-purposed to inhibit FAO in CSCs. 
Similarly, treatment with Doxycycline, another FDA-
approved drug, was sufficient to combat the stimulatory 
effects of Valproic acid on CSC propagation. 
CONCLUSIONS
In summary, we provide new functional evidence 
that Doxycycline-mediated inhibition of mitochondrial 
biogenesis may indeed be sufficient to eliminate hypoxic 
CSCs. Based on these new findings, we believe that future 
Phase II clinical trials may be warranted, to re-purpose 
Doxycycline as an anti-cancer agent targeting chronic 
hypoxia. 
MATERIALS AND METHODS
Materials
Doxycycline, Paclitaxel and Perhexiline Maleate 
were dissolved in DMSO. A 0.01 M solution of paclitaxel 
in DMSO was further diluted with culture medium. Mito 
Tempo, 4-Hydroxy-Tempo and Etomoxir were dissolved 
in H2O. 2-deoxy-D-glucose (2-DG) and Ascorbic Acid 
were dissolved in culture medium. All compounds were 
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from Sigma Aldrich.
Cell cultures
MCF7 breast cancer cells were obtained from ATCC 
and cultured in DMEM (Sigma Aldrich). For hypoxic 
stimulation MCF7 cells were cultured in low glucose 
DMEM (Sigma Aldrich) in a multi-gas N2/CO2 hypoxic 
chamber at 1 % pO2; parallel, MCF7 cells were cultured 
in low glucose DMEM at 21 % O2 to serve as a normoxic 
control. 
Mammosphere formation
A single cell suspension of MCF7 cells previously 
exposed to Normoxia (21% O2) or Hypoxia (1% O2) for 
6h, 72h or 96h was prepared using enzymatic (1x Trypsin-
EDTA, Sigma Aldrich), and manual disaggregation (25 
gauge needle) [42]. Cells were then plated at a density 
of 500 cells/cm2 in mammosphere medium (DMEM-F12/ 
B27 / 20-ng/ml EGF/PenStrep) in nonadherent conditions, 
in culture dishes coated with (2-hydroxyethylmethacrylate) 
(poly-HEMA, Sigma), in the presence of treatments, were 
required. Cells were grown for 5 days and maintained 
in a humidified incubator at 37°C at an atmospheric 
pressure in 5% (v/v) carbon dioxide/air. After 5 days 
for culture, spheres > 50 μm were counted using an eye 
piece graticule, and the percentage of cells plated which 
formed spheres was calculated and is referred to as 
percent mammosphere formation. Mammosphere assays 
were performed in triplicate and repeated three times 
independently.
Evaluation of mitochondrial mass and function
 To measure mitochondrial mass by FACS 
analysis, cells were stained with MitoTracker Deep Red 
(Life Technologies), which localizes to mitochondria 
regardless of mitochondrial membrane potential. Cells 
were incubated with pre-warmed MitoTracker staining 
solution (diluted in PBS/CM to a final concentration of 
10 nM) for 30-60 min at 37 °C. All subsequent steps 
were performed in the dark. Cells were washed in PBS, 
harvested, re-suspended in 300 μL of PBS and then 
analyzed by flow cytometry (Fortessa, BD Bioscience). 
Data analysis was performed using FlowJo software (Tree 
star Inc.). Extracellular acidification rates (ECAR) and 
real-time oxygen consumption rates (OCR) for MCF7 
cells were determined using the Seahorse Extracellular 
Flux (XFe-96) analyzer (Seahorse Bioscience). After 
exposure to Normoxia (21% O2) or Hypoxia (1% O2) 
for 96 h, 15, 000 MCF7 cells per well were seeded into 
XFe-96 well cell culture plates for 24h. Then, cells were 
washed in pre-warmed XF assay media (or for OCR 
measurement, XF assay media supplemented with 10mM 
glucose, 1mM Pyruvate, 2mM L-glutamine and adjusted 
at 7.4 pH). Cells were then maintained in 175 µL/well 
of XF assay media at 37C, in a non-CO2 incubator for 1 
hour. During the incubation time, 5 µL of 80 mM glucose, 
9 µM oligomycin, and 1 M 2-deoxyglucose (for ECAR 
measurement) or 10 µM oligomycin, 9 µM FCCP, 10 µM 
Rotenone, 10 µM antimycin A (for OCR measurement), 
were loaded in XF assay media into the injection ports 
in the XFe-96 sensor cartridge. Data set was analyzed by 
XFe-96 software after the measurements were normalized 
by protein content (SRB). All experiments were performed 
three times independently.
ALDEFLUOR assay and separation of the ALDH 
positive population
ALDH activity was assessed by FACS analysis in 
MCF7 cells cultured for 72 h in Normoxia (21% O2) or 
Hypoxia (1% O2), as well as in MCF7 cells treated with 
Vehicle or Valproic Acid for 72 h. The ALDEFLUOR kit 
(StemCell Technologies) was used to isolate the population 
with high ALDH enzymatic activity by FACS (Fortessa, 
BD Bioscence). Briefly, 1 × 105 MCF7 cells were 
incubated in 1ml ALDEFLUOR assay buffer containing 
ALDH substrate (5 μl/ml) for 40 minutes at 37°C. In each 
experiment, a sample of cells was stained under identical 
conditions with 30 μM of diethylaminobenzaldehyde 
(DEAB), a specific ALDH inhibitor, as negative control. 
The ALDEFLUOR-positive population was established 
in according to the manufacturer’s instructions and was 
evaluated in 3 × 104 cells. Data analysis was performed 
using FlowJo software (Tree star Inc.).
Label-free semi-quantitative proteomics analysis
 Cell lysates were prepared for trypsin digestion 
by sequential reduction of disulphide bonds with TCEP 
and alkylation with MMTS. Then, the peptides were 
extracted and prepared for LC-MS/MS. All LC-MS/MS 
analyses were performed on an LTQ Orbitrap XL mass 
spectrometer (Thermo Scientific, San Jose, CA) coupled to 
an Ultimate 3000 RSLC nano system (Thermo Scientific, 
formerly Dionex, The Netherlands). Xcalibur raw data 
files acquired on the LTQ-Orbitrap XL were directly 
imported into Progenesis LCMS software (Waters Corp., 
Milford, MA, formerly Non-linear dynamics, Newcastle 
upon Tyne, UK) for peak detection and alignment. Data 
were analyzed using the Mascot search engine. Five 
technical replicates were analyzed for each sample type 
[10, 11].
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Evaluation of reactive oxygen species
Reactive oxygen species (ROS) production was 
measured by FACS analysis using CM-H2DCFDA 
(C6827, Life Technologies), a cell-permeable probe that 
is non-fluorescent until oxidation within the cell. MCF7 
cells were cultured upon Normoxia (21% O2) or Hypoxia 
(1% O2) for 6 hrs or 96 hrs. Thereafter, cells were washed 
with PBS, and incubated at 37°C for 20 min with 1 μM 
CM-H2DCFDA, diluted in PBS/CM. All subsequent steps 
were performed in the dark. Cells were rinsed, harvested, 
re-suspended in PBS/CM and then analyzed by flow 
cytometry (Fortessa, BD Bioscience). ROS levels were 
estimated by using the mean fluorescent intensity of the 
viable cell population. The results were analyzed using 
FlowJo software (Tree star Inc.).
Western blot analysis
MCF7 cell protein lysates were electrophoresed 
through a reducing SDS/10% (w/v) polyacrylamide gel, 
electroblotted onto a nitrocellulose membrane and probed 
with primary antibodies against HIF-1 R & D Systems 
phosphorylated ERK 1/2 (E-4), ERK2 (C-14), TOMM20 
(F-10) and β-actin (C2), all purchased from Santa Cruz 
Biotechnology. Proteins were detected by horseradish 
peroxidase-linked secondary antibodies and revealed using 
the SuperSignal west pico chemiluminescent substrate 
(Fisher Scientific).
Statistical analysis
Data is represented as the mean ± standard error of 
the mean (SEM), taken over ≥ 3 independent experiments, 
with ≥ 3 technical replicates per experiment, unless 
otherwise stated. Statistical significance was measured 
using the t-test. P ≤ 0.05 was considered significant.
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